Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects

PR Newswire January 12, 2021

Lipocine to Present at the H.C. Wainwright BioConnect 2021 Conference

PR Newswire January 4, 2021

Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study

PR Newswire December 30, 2020

Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics

PR Newswire December 29, 2020

Lipocine Announces Tentative Approval of TLANDO(TM)

PR Newswire December 8, 2020

Lipocine Announces Deletion of Unauthorized Changes to Company's Website

PR Newswire December 8, 2020

Lipocine Provides New Regulatory Update on TLANDO(TM)

PR Newswire December 4, 2020

Lipocine Announces Third Quarter 2020 Financial and Operational Results

PR Newswire November 10, 2020

Lipocine Provides Regulatory Update on TLANDO(TM)

PR Newswire November 6, 2020

Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience(TM)

PR Newswire November 5, 2020

Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

PR Newswire October 14, 2020

Lipocine to Present at the H.C. Wainwright 4th Annual NASH Investor Conference

PR Newswire September 29, 2020

Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study

PR Newswire September 21, 2020

Lipocine to Participate in HC Wainwright Annual Global Investment Conference

PR Newswire September 8, 2020

Lipocine Provides Regulatory Update for TLANDO(TM)

PR Newswire August 28, 2020

Lipocine Announces Second Quarter 2020 Financial and Operational Results

PR Newswire August 6, 2020

Lipocine Announces Publication of LPCN 1144 Liver Fat Study ("LFS") Results

PR Newswire August 3, 2020

Lipocine Announces Derivative Suit Was Dismissed

PR Newswire July 31, 2020

Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement

PR Newswire July 13, 2020

Lipocine Announces Presentations on TLANDO(TM) at AUA Virtual Experience 2020

PR Newswire May 15, 2020